On Thursday, Shares of Huntington Bancshares Incorporated (NASDAQ:HBAN), subtract -2.51% and closed at $9.72 in the last trading session. The last trading range of the stock ranges between $9.57 and $9.92. Huntington Bancshares Incorporated operates as a holding company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services. The companys Retail and Business Banking segment offers financial products and services, counting checking accounts, savings accounts, money market accounts, certificates of deposit, consumer loans, and small business loans; and investments, insurance, interest rate risk protection, and foreign exchange and treasury administration services. Its Commercial Banking segment provides corporate risk administration and institutional sales, trading, and underwriting services; commercial property and casualty, employee benefits, personal lines, life and disability, and specialty lines of insurance; and brokerage and agency services for residential and commercial title insurance, in addition to excess and surplus product lines of insurance. The companys Automobile Finance and Commercial Real Estate segment offers financing for the purchase of vehicles; financing the acquisition of new and used vehicle inventory of franchised automotive dealerships; and financing for land, buildings, and other commercial real estate owned or constructed by real estate developers, automobile dealerships, or other customers. Its Regional Banking and The Huntington Private Client Group segment provides deposits, lending, and other banking services; wealth administration services, and retirement plan and corporate trust services; and brokerage, annuities, advisory, and other investment products.
Sanofi SA (ADR)(NYSE:SNY), dropped -0.58% and closed at $37.73 in the last trading session. The last trading range of the stock ranges between $37.20 and $37.86. The company’s Market capitalization is $96.32 Billion with the total outstanding Shares of 1.29 billion. A new survey of 505 American adults (18 years of age and older) who self-stated being diagnosed with moderate-to-severe atopic dermatitis (AD) shows that the disease goes beyond the physical signs and symptoms, negatively impacting people’s lives socially and psychologically. The results, unveiled recently during Eczema Awareness Month, show that a majority of respondents are making lifestyle modifications, and that some have made career choices that limit face-to-face interactions with others because of the disease. The survey, part of the national awareness campaign Understand AD, was conducted online by Harris Poll on behalf of Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.
“We hear first-hand from people living with this disease that many aspects of their everyday life are influenced,” said Julie Block, President and CEO, National Eczema Association. “They routinely deal with intense itch and pain, and feeling self-conscious because of the way their skin looks. People share that they feel depressed and anxious because of their disease.”
Out of the 505 Americans with moderate-to-severe atopic dermatitis who responded to the Understand AD survey:
- 53 percent stated that their disease has negatively influenced their daily lives
- 82 percent have made lifestyle modifications, such as avoiding social engagements, being in pictures and participating in sports/exercise
- 55 percent stated that their confidence was negatively influenced because of their disease
- 49 percent say their sleep has been negatively influenced by the disease, moderately or significantly
- 23 percent of people feel depressed and 28 percent feel anxious because of their AD
- 20 percent report that their AD has influenced their ability to maintain employment and 16 percent have made career choices that limit face-to-face interactions with others because of the disease
PulteGroup, Inc. (NYSE:PHM), dropped -1.72% and closed at $19.40 in the last trading session. The last trading range of the stock ranges between $19.34 and $19.65. During the 52-week trading session the minimum price at which share price traded, registered at $14.61 and reached to max level of $22.40. The data was presented at an oral session at the European Society of Medical Oncology (abstract #2333)
The study meets its primary objective obtaining an overall response rate (ORR) in 41% of the patients. In the BRCA 2 subgroup, the ORR was 61%, while in those patients with BRCA 1, this was 26%
PharmaMar (PHM) has declared the positive results of its Phase II study of lurbinectedin (PM1183) in patients with BRCA 1 / 2 -associated metastatic breast cancer, who had formerly received a maximum of 3 prior chemotherapy regimens.
About, 5-10% of breast cancers are associated with the BRCA 1 or 2 hereditary mutations. For the moment the treatment of these patients is similar to any other type of breast cancers, that is mainly conditioned by their hormone receptor and HER2 status. However, recent studies around the mutation demonstrate that these types of tumors behave differently in breast cancer, therefore, the patients harboring these mutations could benefit from a more specific treatment.
Doctor Judith Balmaña, oncology expert from the Vall D´Hebron Institute of Oncology, and principal investigator of the trial, presented the data at an oral session at the European Society of Medical Oncology (ESMO) Congress, being held in Copenhagen, Denmark, that started on the 7th and running to the 11th of October.